Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute (NCI)
OBJECTIVES:
I. Determine the objective response rate to flavopiridol by patients with previously treated intermediate and high grade non-Hodgkin's lymphoma and mantle cell lymphoma.
II. Determine the toxicity of flavopiridol administered as a continuous infusion every 2 weeks in these patients.
III. Study the pharmacokinetics of flavopiridol in these patients.
OUTLINE: This is an open label, multi-institutional study.
Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs. Patients are followed until death.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma with clinical or pathological evidence of recurrent disease
Measurable or evaluable disease
CNS metastases not requiring intravenous steroid therapy allowed
PATIENT CHARACTERISTICS:
Age: 18 and over
Performance status: CALGB 0-2
Life expectancy: At least 12 weeks
Absolute neutrophil count at least 1500/mm3 (unless due to bone marrow involvement by lymphoma)
Platelet count at least 100,000/mm3 (unless due to bone marrow involvement by lymphoma)
At least 7 days since platelet transfusion
Hemoglobin at least 9.0 g/dL
Bilirubin no greater than 1.5 mg/dL
Transaminases no greater than 2.5 times upper limit of normal
Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min
No significant uncontrolled medical or psychiatric illness
No active serious infection
Not pregnant or lactating
Fertile patients must use effective contraception
Central venous catheter required prior to study entry
PRIOR CONCURRENT THERAPY:
No more than 1 prior chemotherapy regimen
At least 4 weeks since prior chemotherapy and recovered from all toxic effects Prior chemotherapy must contain anthracycline if intermediate or high-grade NHL other than mantle cell
No concurrent treatment with other chemotherapeutic or investigational antineoplastic drugs
At least 4 weeks since prior radiation therapy and recovered (Site of only measurable disease must not be located within prior radiation therapy port)
No concurrent radiation therapy to any lesion
Clareo Health | Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
